DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $274,235,102 | +0.7% | 1,105,341 | -2.6% | 0.42% | +9.4% |
| Q2 2023 | $272,436,000 | -6.2% | 1,135,150 | -1.5% | 0.38% | -10.9% |
| Q1 2023 | $290,397,211 | -5.8% | 1,152,187 | -0.8% | 0.43% | -10.7% |
| Q4 2022 | $308,332,309 | +4.5% | 1,161,677 | +1.7% | 0.48% | -3.0% |
| Q3 2022 | $295,165,000 | +2.0% | 1,142,765 | +0.2% | 0.50% | +9.0% |
| Q2 2022 | $289,259,000 | -9.4% | 1,140,971 | +4.8% | 0.46% | +9.0% |
| Q1 2022 | $319,367,000 | -15.7% | 1,088,762 | -5.5% | 0.42% | -5.2% |
| Q4 2021 | $378,911,000 | +9.0% | 1,151,670 | +0.9% | 0.44% | -0.7% |
| Q3 2021 | $347,611,000 | +12.5% | 1,141,804 | -0.8% | 0.45% | +14.9% |
| Q2 2021 | $308,992,000 | +15.0% | 1,151,408 | -3.5% | 0.39% | +9.3% |
| Q1 2021 | $268,695,000 | +0.9% | 1,193,777 | -0.4% | 0.36% | -4.8% |
| Q4 2020 | $266,367,000 | +5.2% | 1,199,096 | +2.0% | 0.37% | -8.1% |
| Q3 2020 | $253,158,000 | +21.4% | 1,175,675 | -0.3% | 0.41% | +10.6% |
| Q2 2020 | $208,512,000 | +35.8% | 1,179,168 | +6.3% | 0.37% | +10.9% |
| Q1 2020 | $153,505,000 | -10.2% | 1,109,059 | -0.4% | 0.33% | +13.7% |
| Q4 2019 | $170,871,000 | +10.6% | 1,113,313 | +4.1% | 0.29% | -3.3% |
| Q3 2019 | $154,452,000 | +1.4% | 1,069,390 | +0.3% | 0.30% | 0.0% |
| Q2 2019 | $152,354,000 | +10.0% | 1,066,012 | +1.6% | 0.30% | +6.0% |
| Q1 2019 | $138,524,000 | +27.4% | 1,049,266 | -0.5% | 0.28% | +15.0% |
| Q4 2018 | $108,744,000 | -5.5% | 1,054,537 | -0.5% | 0.25% | +10.3% |
| Q3 2018 | $115,117,000 | +10.1% | 1,059,423 | +0.0% | 0.22% | +2.8% |
| Q2 2018 | $104,512,000 | +1.8% | 1,059,105 | +1.0% | 0.22% | -0.9% |
| Q1 2018 | $102,683,000 | +2.3% | 1,048,753 | -3.0% | 0.22% | +6.8% |
| Q4 2017 | $100,404,000 | +8.6% | 1,081,708 | +0.4% | 0.21% | +0.5% |
| Q3 2017 | $92,425,000 | -6.7% | 1,077,462 | -8.3% | 0.20% | -2.8% |
| Q2 2017 | $99,111,000 | -6.1% | 1,174,432 | -4.8% | 0.21% | -0.9% |
| Q1 2017 | $105,540,000 | +5.2% | 1,233,949 | -4.3% | 0.21% | +4.4% |
| Q4 2016 | $100,316,000 | -3.2% | 1,288,749 | -2.5% | 0.20% | -4.7% |
| Q3 2016 | $103,643,000 | -21.7% | 1,322,149 | +0.8% | 0.21% | -24.9% |
| Q2 2016 | $132,416,000 | +7.7% | 1,311,049 | +1.2% | 0.28% | +8.8% |
| Q1 2016 | $122,928,000 | +16.8% | 1,295,888 | +14.3% | 0.26% | +1.9% |
| Q4 2015 | $105,278,000 | +10.8% | 1,133,484 | +1.6% | 0.26% | +4.0% |
| Q3 2015 | $95,053,000 | -1.8% | 1,115,519 | -1.3% | 0.25% | +5.6% |
| Q2 2015 | $96,778,000 | -0.1% | 1,130,715 | -0.9% | 0.23% | +2.2% |
| Q1 2015 | $96,845,000 | -2.6% | 1,140,693 | -1.6% | 0.23% | -1.7% |
| Q4 2014 | $99,382,000 | +13.9% | 1,159,520 | +1.0% | 0.23% | +7.9% |
| Q3 2014 | $87,271,000 | -0.1% | 1,148,602 | +3.5% | 0.22% | -1.8% |
| Q2 2014 | $87,334,000 | +6.9% | 1,109,283 | +1.9% | 0.22% | +1.9% |
| Q1 2014 | $81,666,000 | -2.4% | 1,088,883 | +0.5% | 0.22% | -4.4% |
| Q4 2013 | $83,668,000 | +12.1% | 1,083,783 | +0.7% | 0.23% | +1.8% |
| Q3 2013 | $74,615,000 | +13.0% | 1,076,383 | +3.2% | 0.22% | +3.7% |
| Q2 2013 | $66,030,000 | +5.3% | 1,043,129 | +3.4% | 0.21% | +1.9% |
| Q1 2013 | $62,725,000 | – | 1,009,252 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |